Testicular metastases from renal cell carcinoma (RCC) are extremely rare. Tyrosine kinase inhibitors (TKI) are the cornerstone of systemic therapy for metastatic RCC. We report a case of testicular metastasis in a 72-year-old patient with RCC that developed 17 years after nephrectomy and response to TKI treatment, a retrospective literature search on testicular metastases from RCC, and the indirect evidence described in the literature on the efficacy of chemotherapy and target therapy on testicular lesions.
Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report
Turco F.;Tucci M.;Di Stefano R. F.;Samuelly A.;Bungaro M.;Scagliotti G. V.;Buttigliero C.
2021-01-01
Abstract
Testicular metastases from renal cell carcinoma (RCC) are extremely rare. Tyrosine kinase inhibitors (TKI) are the cornerstone of systemic therapy for metastatic RCC. We report a case of testicular metastasis in a 72-year-old patient with RCC that developed 17 years after nephrectomy and response to TKI treatment, a retrospective literature search on testicular metastases from RCC, and the indirect evidence described in the literature on the efficacy of chemotherapy and target therapy on testicular lesions.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer_ Case report.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
507.18 kB
Formato
Adobe PDF
|
507.18 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
